Weight Management


STEP 1 and STEP 3 Results with Thomas Wadden, PhD

March 02, 2021

Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.

Digital Self-Monitoring Linked to Improvements in Weight Loss Trials

February 24, 2021

A review of 39 randomized clinical trials examining weight loss interventions is providing clinicians with an overview of engagement rates, mediums used, and effects of digital self-monitoring for weight loss among obese or overweight patients.

Case Report: Shortness of Breath After Cefalexin

February 18, 2021

Our latest case report from Brady Pregerson, MD, features a 62 y/o male with a history of obesity, CAD, anxiety, and COPD presenting with SOB after stating cefalexin. Can you determine the correct diagnosis?